KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Travere Therapeutics (TVTX) Interest & Investment Income (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Interest & Investment Income for 13 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest & Investment Income fell 31.7% year-over-year to $2.6 million, compared with a TTM value of $12.7 million through Dec 2025, down 28.6%, and an annual FY2025 reading of $12.7 million, down 28.6% over the prior year.
  • Interest & Investment Income was $2.6 million for Q4 2025 at Travere Therapeutics, down from $3.0 million in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $11.6 million in Q2 2023 and bottomed at -$9.9 million in Q4 2021.
  • Average Interest & Investment Income over 5 years is $1.4 million, with a median of $3.1 million recorded in 2022.
  • The sharpest move saw Interest & Investment Income crashed 903.33% in 2022, then surged 491.12% in 2023.
  • Year by year, Interest & Investment Income stood at -$9.9 million in 2021, then surged by 131.56% to $3.1 million in 2022, then surged by 129.6% to $7.2 million in 2023, then tumbled by 46.94% to $3.8 million in 2024, then plummeted by 31.7% to $2.6 million in 2025.
  • Business Quant data shows Interest & Investment Income for TVTX at $2.6 million in Q4 2025, $3.0 million in Q3 2025, and $3.3 million in Q2 2025.